Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLYTE: Coltuximab Ravtansine in Relapsed/Refractory DLBCL
NCT01472887Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2012
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
A Phase 2 trial of coltuximab ravtansine in diffuse large B-cell lymphoma (DLBCL), sponsored by Sanofi. Started Jan 2012; status: completed.
02
Drugs
coltuximab ravtansine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01472887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01472887.